PenderFund Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

PenderFund Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$559K	Buy	+17,800	New	+$525K	0.07%	91

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PenderFund Capital Management's CPRX Position: Q2 2026 in Review

PenderFund Capital Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 17,800 shares worth $559K. The stake represents 0.07% of the portfolio and ranks #91 among its holdings.

396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

PenderFund Capital Management held 17,800 shares of Catalyst Pharmaceutical worth $559K as of Q2 2026.
Catalyst Pharmaceutical was a new PenderFund Capital Management position in Q2 2026.
Catalyst Pharmaceutical made up 0.07% of PenderFund Capital Management's portfolio in Q2 2026, its #91 holding.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on PenderFund Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.